Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
ViiV applies for FDA approval of HIV drug fostemsavir
The Food and Drug Administration declined approval of ViiV Healthcare’s injectable HIV regimen Cabenuva.
Read the digital edition!
The FDA recently held up the U.S. approval based on concerns over the monthly injectable regimen’s manufacturing.
Whether given every four or eight weeks, long-acting injections of cabotegravir and rilpivirine suppressed HIV equally well.
The attachment inhibitor performed well as an adjunct to an optimized antiretroviral regimen among those with multidrug-resistant HIV.
The Food and Drug Administration approves once-daily Descovy for PrEP.
The authors of the largest study to date to analyze condoms’ failure rate are pushing the FDA to finally approve them for anal sex use.
Acting Commissioner Ned Sharpless will return to lead the National Cancer Institute.
The new indication is for prevention of sexually transmitted HIV, with the exception of transmission via receptive vaginal sex.
The indication for AbbVie’s regimen includes those with compensated cirrhosis.
These medications can now be used by people on stable antiretroviral treatment with undetectable viral load.
Pretomanid triple therapy cuts the length of treatment from 18 months to six months.
Evidence supports new PrEP option for gay men and trans women, but there’s no consensus for other groups.
The Food and Drug Administration has approved a new treatment for people living with HIV.
Previously, tests were approved only for use with genital or urine samples.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.